Expression and localisation of CYP2D enzymes in rat basal ganglia

Brain Research

Volumn 822, Issue 1-2, 1999, Pages 175-191

  Riedl, Andrew G ^a   Watts, Paul M ^a,c   Edwards, Robert J ^b   Schulz Utermoehl, Timothy ^b   Boobis, Alan R ^b   Jenner, Peter ^a   Marsden, C David ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Basal ganglia; Brain; CYP2D; Immunohistochemistry; P450; Parkinson's disease

Indexed keywords

CLOZAPINE; CYTOCHROME P450; ENZYME; PEROXIDASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME LOCALIZATION; ENZYME REGULATION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; STRESS; SUBSTANTIA NIGRA;

EID: 0033586335     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01113-0     Document Type: Article

References (65)

1. M. Armstrong, A.K. Daly, S. Cholerton, D.N. Bateman, J.R. Idle, Mutant debrisoquine hydroxylation genes in Parkinson's disease, Lancet 339 (1992) 1017-1018.
2. R.J. Baldessarini, F. Centorrino, J.G. Flood, S.A. Volpicelli, D. Huston-Lyons, B.M. Cohen, Tissue concentrations of clozapine and its metabolites in the rat, Neuropharmacology 9 (1993) 117-124.
3. J.M. Ball, N.L. Henry, R.C. Montelaro, M.J. Newman, A versatile synthetic peptide-based ELISA for identifying antibody epitopes, J. Immunol. Methods 17 (1994) 37-44.
4. P.A. Ballard, J.W. Tetrud, J.W. Langston, Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases, Neurology 35 (1985) 949-956.
5. A. Barbeau, Etiology of Parkinson's disease: a research strategy, Can. J. Neurol. Sci. 11 (1984) 24-28.
6. A. Barbeau, M. Roy, S. Paris, T. Cloutier, L. Plasse, J. Poirier, Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine, Lancet 2 (1985) 1213-1216.
7. L.O. Baum, H.W. Strobel, Regulation of expression of cytochrome P-450 2D mRNA in rat brain with steroid hormones, Brain Res. 765 (1997) 67-73.
8. A.F. Bergh, H.W. Strobel, Anatomical distribution of NADPH-cytochrome P450 reductase and cytochrome P4502D forms in rat brain: effects of xenobiotics and sex steroids, Mol. Cell Biochem. 162 (1996) 31-41.
9. A.R. Boobis, M.J. Brodie, G.C. Kahn, D.R. Fletcher, J.H. Saunders, D. DS, Monooxygenase activity of human liver in microsomal fractions of neddle biopsy specimens, Br. J. Clin. Pharmacol. 9 (1980) 11-19.
10. T. Coleman, S.W. Ellis, I.J. Martin, M.S. Lennard, G.T. Tucker, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's disease, J. Pharmacol. Exp. Ther. 277 (1996) 685-690.
11. R.J. Edwards, B.P. Murray, S. Murray, T. Schulz, D. Neubert, T.W. Gant, S.S. Thorgeirsson, A.R. Boobis, D.S. Davies, Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human, Carcinogenesis 15 (1994) 829-836.
12. R.J. Edwards, A.M. Singleton, B.P. Murray, D.S. Davies, A.R. Boobis, Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes, Biochem. Pharmacol. 49 (1995) 39-47.
13. R.J. Edwards, A.M. Singleton, D. Sesardic, A.R. Boobis, D.S. Davis, Antibodies to a synthetic peptide that react specifically with a common surface region on two hydrocarbon-inducible isoenzymes of cytochrome P-450 in the rat, Biochem. Pharmacol. 37 (1988) 3735-3741.
14. R. Fonne-Pfister, M.J. Bargetzi, U.A. Meyer, MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P-450 isozymes (P450bufI, P450db1) catalysing debrisoquine 4-hydroxylation, Biochem. Biophys. Res. Commun. 148 (1987) 1144-1150.
15. T. Hansson, N. Tindberg, M. Ingelman-Sundberg, C. Kohler, Regional distribution of ethanol-inducible cytochrome P-450 IIE1 in the rat central nervous system, Neuroscience 34 (1990) 451-463.
16. E. Hedlund, A. Wyss, T. Kainu, M. Backlund, C. Kohler, M. Pelto-Huikko, J.A. Gustafsson, M. Warner, Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene, Mol. Pharmacol. 50 (1996) 342-350.
17. T. Hiroi, S. Imaoka, T. Chow, Y. Funae, Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR, Biochim. Biophys. Acta 1380 (1998) 305-312.
18. T. Hiroi, S. Imaoka, Y. Funae, Dopamine formation from tyramine by CYP2D6, Biochem. Biophys. Res. Commun. 249 (1998) 838-843.
19. K. Iwahashi, H. Suwaki, Y. Matsuo, Y. Ichikawa, K. Hosokawa, Correspondence of increased debrisoquine 4-monooxygenase activity with seizure-susceptibility in Mongolian gerbils, J. Neurol. Sci. 121 (1994) 18-21.
20. F.J. Jimenez-Jimenez, C. Tabernero, M.A. Mena, J. Garcia de Yebenes, M.J. Garcia de Yebenes, M.J. Casarejos, B. Pardo, J.A. Garcia-Agundez, J. Benitez, A. Martinez, J.A.L. Garcia-Asenjo, Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine, J. Neurochem. 57 (1991) 81-87.
21. G.C. Kahn, M. Rubenfield, D.S. Davies, S. Murray, A.R. Boobis, Sex and strain differences in hepatic debrisoquine 4-hydroxylase activity of the rat, Drug Metab. Dispos. 13 (1985) 510-516.
22. H. Kawashima, D.J. Sequeira, D.R. Nelson, H.W. Strobel, Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18 catalysing imipramine N-demethylation, J. Biol. Chem. 271 (1996) 28176-28180.
23. M. Komori, A novel P450 expressed at high level in rat brain, Biochem. Biophys. Res. Commun. 196 (1993) 721-728.
24. J.F.R. Konig, R.A. Klippel, The Rat Brain: A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem, Williams and Williams, Baltimore, 1963.
25. K. Kurokohchi, Y. Matsuo, H. Yoneyama, K. Nishioka, Y. Ichikawa, Interleukin-2 induction of cytochrome P450-linked monooxygenase systems of rat liver microsomes, Biochem. Pharmacol. 45 (1993) 585-592.
26. D.G. LeCouteur, P.W. Leighton, S.J. McCann, S.M. Pond, Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease, Mov. Disord. 12 (1997) 760-763.
27. C.S. Lee, H. Sauer, A. Bjorklund, Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat, Neuroscience 72 (1996) 641-653.
28. Y.H. Lee, M. Yano, S.Y. Liu, E. Matsunaga, P.F. Johnson, F.J. Gonzalez, A novel cis-acting element controlling the rat CYP2D5 gene and requiring cooperativity between C/EBPß and an Sp1 factor, Mol. Cell Biol. 14 (1994) 1383-1394.
29. E.D. Lephart, P.C. Butler, R.H. Mills, N.A. Jacobson, D.R. Ladle, G.J. Bloch, Effects of testosterone and progesterone on brain 5 alpha-reductase and aromatase in Long-Evans males and comparison of aromatase in Long-Evans vs. Sprague-Dawley rats, Brain Res. 789 (1998) 327-330.
30. C. Martinez, J.A.G. Agundez, G. Gervasini, R. Martin, J. Benitez, Tryptamine: a possible endogenous substrate for CYP2D6, Pharmacogenetics 7 (1997) 85-93.
31. E. Matsunaga, U.M. Zanger, J.P. Hardwick, H.V. Gelboin, U.A. Meyer, F.J. Gonzalez, The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats, Biochemistry 28 (1989) 7349-7355.
32. Y. Matsuo, K. Iwahashi, Y. Ichikawa, Debrisoquine 4-monooxygenase and bufuralol 1′-monooxygenase activities in bovine and rabbit tissues, Biochem. Pharmacol. 43 (1992) 1911-1919.
33. M.C.E. McFadyen, W.T. Melvin, G.I. Murray, Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain, Biochem. Pharmacol. 55 (1998) 825-830.
34. N.A. Mufti, M.L. Shuler, Possible role of arachidonic acid in stress-induced cytochrome P4501A1 activity, Biotechnol. Prog. 12 (1996) 847-854.
35. G.I. Murray, M.D. Burke, Immunocytochemistry of drug-metabolising enzymes, Biochem. Pharmacol. 50 (1995) 895-903.
36. S. Narimatsu, M. Tachibana, Y. Masubuchi, T. Suzuki, Cytochrome P4502D and -2C enzymes catalyze the oxidative N-demethylation of the Parkinsonism-inducing substance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rat liver microsomes, Chem. Res. Toxicol. 9 (1996) 93-98.
37. 3H]GB R-12935 binding proteins, Arch. Biochem. Biophys. 276 (1990) 424-432.
38. P.J. Norris, J.P. Hardwick, P.C. Emson, Regional distribution of cytochrome P450 2D1 in the rat central nervous system, J. Comp. Neurol. 366 (1996) 244-258.
39. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, London, 1986.
40. P.J. Perry, D.D. Miller, S.V. Arndt, R.J. Cadoret, Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients, Am. J. Psychiatry 148 (1991) 231-235.
41. V. Plante-Bordeneuve, D. Taussig, F. Thomas, G. Said, N.W. Wood, C.D. Marsden, A.E. Harding, Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele, Neurology 48 (1997) 1589-1593.
42. S.P. Raps, J.C.K. Lai, L. Hertz, A.J.L. Cooper, Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons, Brain Res. 493 (1989) 398-401.
43. A.G. Riedl, P.M. Watts, R.J. Edwards, A.R. Boobis, P. Jenner, C.D. Marsden, Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera, Brain Res. 743 (1996) 324-328.
44. A.G. Riedl, P.M. Watts, P. Jenner, C.D. Marsden, P450 enzymes and Parkinson's disease: the story so far, Mov. Disord. 13 (1998) 212-220.
45. M.S. Sandy, M. Armstrong, C.M. Tanner, A.K. Daly, D.A. Di-Monte, J.W. Langston, J.R. Idle, CYP2D6 allelic frequencies in young-onset Parkinson's disease, Neurology 47 (1996) 225-230.
46. T. Schulz-Utermoehl, A.J. Bennett, S.W. Ellis, G.T. Tucker, A.R. Boobis, R.J. Edwards, Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression, Pharmacogenetics (In Press).
47. G.S. Shahi, N.P. Das, S.M. Moochhala, Parkinson's disease and cytochrome P450: a possible link?, Med. Hypotheses 32 (1990) 277-282.
48. T.G. Sherman, C.A. Moody, Alterations in tyrosine hydroxylase expression following partial lesions of the nigrostriatal bundle, Mol. Brain Res. 29 (1995) 285-296.
49. C.A.D. Smith, A.C. Gough, P.N. Leigh, B.A. Summers, A.E. Harding, D.M. Maranganore, S.G. Sturman, A.H.V. Schapira, A.C. Williams, N.K. Spurr, C.R. Wolf, Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease, Lancet 339 (1992) 1375-1377.
50. M.J. Steiger, P. Lledo, N.P. Quinn, C.D. Marsden, P. Turner, P.G. Jenner, Debrisoquine hydroxylation in Parkinson's disease, Acta Neurol. Scand. 86 (1992) 159-164.
51. H.W. Strobel, J. Geng, H. Kawashima, H. Wang, Cytochrome P450-dependent biotransformation of drugs and other xenobiotic substrates in neural tissue, Drug Metab. Rev. 29 (1997) 1079-1105.
52. H.W. Strobel, H. Kawashima, J. Geng, D. Sequeira, A. Bergh, A.V. Hodgson, H.M. Wang, S.J. Shen, Expression of multiple forms of brain cytochrome P450, Toxicol. Lett. 82 (1995) 639-643.
53. T. Suzuki, S. Fujita, S. Narimatsu, Y. Masubuchi, M. Tachibana, S. Ohta, M. Hirobe, Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes, FASEB J. 6 (1992) 771-776.
54. C.M. Tanner, The role of environmental toxins in the etiology of Parkinson's disease, Trends Neurosci. 12 (1989) 49-54.
55. R.F. Tyndale, R. Sunahara, T. Inaba, W. Kalow, F.J. Gonzalez, H.B. Niznik, Neuronal cytochrome P450IID1 (Debrisoquine/Sparteine-type): potent inhibition of activity by (-)cocaine and nucleotide sequence identity to human hepatic P450 gene CYP 2D6, Mol. Pharmacol. 40 (1991) 63-68.
56. C. Van Hartesveldt, J.N. Joyce, Effect of estrogen on the basal ganglia, Neurosci. Biobehav. Rev. 10 (1986) 1-14.
57. J. Wan, S. Imaoka, T. Chow, T. Hiroi, Y. Yabusaki, Y. Funae, Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity, Arch. Biochem. Biophys. 348 (1997) 383-390.
58. M. Warner, H. Hellmold, S. Yoshida, D. Liao, E. Hedlund, J.A. Gustafsson, Cytochrome P450 in the breast and brain: role in tissue-specific activation of xenobiotics, Mutat. Res. 376 (1997) 79-85.
59. M. Warner, M. Stromstedt, A. Wyss, S. Yoshida, J.A. Gustafsson, Induction of brain P450 by solvents and pharmaceuticals, in: M.C. Lechner (Ed.), Cytochrome P450, 8th International Conference, John Libbey Eurotext, Paris, 1994, pp. 81-88.
60. M. Warner, A. Wyss, S. Yoshida, J.A. Gustafsson, Cytochrome P450 enzymes in brain, Methods Neurosci. 22 (1994) 51-66.
61. P.M. Watts, A.G. Riedl, D.C. Douek, R.J. Edwards, A.R. Boobis, P. Jenner, C.D. Marsden, Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase, Neuroscience 86 (1998) 511-519.
62. R.W. Williams, P. Rakic, Three-dimensional counting: an accurate and direct method to estimate numbers of cells in sectioned material, J. Comp. Neurol. 278 (1988) 344-352.
63. N. Wood, Genes and parkinsonism, J. Neurol. Neurosurg. Psychiatry 62 (1997) 305-309.
64. A. Wyss, J.A. Gustafsson, M. Warner, Cytochromes P450 of the 2D subfamily in rat brain, Mol. Pharmacol. 47 (1995) 1148-1155.
65. Y. Yamamoto, A. Nakamura, T. Tasaki, S. Umeda, C. Sugimoto, S. Imaoka, Y. Funae, M. Masuda, A. Kazusaka, S. Fujita, Impaired expression in DA rats of catalytic active P450BTL, immunochemically distinguishable from P4502D1-immunological evidence with specific antipeptide antibodies, Biomed. Res. 17 (1996) 331-337.